日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

A guided chatbot-based psychological intervention for psychologically distressed older adolescents and young adults: a randomised clinical trial in Jordan

一项针对心理困扰的青少年和青年人的基于引导式聊天机器人的心理干预:约旦的一项随机临床试验

Bryant, Richard A; de Graaff, Anne M; Habashneh, Rand; Fanatseh, Sarah; Keyan, Dharani; Akhtar, Aemal; Abualhaija, Adnan; Faroun, Muhannad; Aqel, Ibrahim Said; Dardas, Latefa; Afar, Hadeel; Servili, Chiara; Hadzi-Pavlovic, Dusan; van Ommeren, Mark; Carswell, Kenneth

Egg multivesicular bodies elicit an LC3-associated phagocytosis-like pathway to degrade paternal mitochondria after fertilization

受精后,卵子多泡体引发 LC3 相关吞噬样途径,降解父系线粒体

Sharon Ben-Hur, Shoshana Sernik, Sara Afar, Alina Kolpakova, Yoav Politi, Liron Gal, Anat Florentin, Ofra Golani, Ehud Sivan, Nili Dezorella, David Morgenstern, Shmuel Pietrokovski, Eyal Schejter, Keren Yacobi-Sharon, Eli Arama

First-in-human phase 1 study of budigalimab, an anti-PD-1 inhibitor, in patients with non-small cell lung cancer and head and neck squamous cell carcinoma

布地加利单抗(一种抗PD-1抑制剂)在非小细胞肺癌和头颈部鳞状细胞癌患者中的首次人体I期研究

Italiano, Antoine; Cassier, Philippe A; Lin, Chia-Chi; Alanko, Tuomo; Peltola, Katriina J; Gazzah, Anas; Shiah, Her-Shyong; Calvo, Emiliano; Cervantes, Andrés; Roda, Desamparados; Tosi, Diego; Gao, Bo; Millward, Michael; Warburton, Lydia; Tanner, Minna; Englert, Stefan; Lambert, Stacie; Parikh, Apurvasena; Afar, Daniel E; Vosganian, Gregory; Moreno, Victor

Association of Baseline and Pharmacodynamic Biomarkers With Outcomes in Patients Treated With the PD-1 Inhibitor Budigalimab

接受 PD-1 抑制剂 Budigalimab 治疗的患者基线和药效学生物标志物与疗效的关系

Stacie L Lambert, Chun Zhang, Claire Guo, Tolga Turan, David L Masica, Stefan Englert, Yuni Fang, James Sheridan, Robert Tyler McLaughlin, Catherine Tribouley, Greg Vosganian, Daniel Afar

Model Informed Dosing Regimen and Phase I Results of the Anti-PD-1 Antibody Budigalimab (ABBV-181)

基于模型指导的抗PD-1抗体布地利单抗(ABBV-181)给药方案及I期临床试验结果

Powderly, John; Spira, Alexander; Kondo, Shunsuke; Doi, Toshihiko; Luke, Jason J; Rasco, Drew; Gao, Bo; Tanner, Minna; Cassier, Philippe A; Gazzah, Anas; Italiano, Antoine; Tosi, Diego; Afar, Daniel E; Parikh, Apurvasena; Engelhardt, Benjamin; Englert, Stefan; Lambert, Stacie L; Kasichayanula, Sreeneeranj; Mensing, Sven; Menon, Rajeev; Vosganian, Gregory; Tolcher, Anthony

Reaction of Lectin-Specific Antibody with Human Tissue: Possible Contributions to Autoimmunity

凝集素特异性抗体与人体组织的反应:可能与自身免疫有关

Vojdani, Aristo; Afar, Daniel; Vojdani, Elroy

Phase I trial of anti-CS1 monoclonal antibody elotuzumab in combination with bortezomib in the treatment of relapsed/refractory multiple myeloma

抗CS1单克隆抗体elotuzumab联合硼替佐米治疗复发/难治性多发性骨髓瘤的I期临床试验

Jakubowiak, Andrzej J; Benson, Don M; Bensinger, William; Siegel, David S D; Zimmerman, Todd M; Mohrbacher, Ann; Richardson, Paul G; Afar, Daniel E H; Singhal, Anil K; Anderson, Kenneth C

CS1 promotes multiple myeloma cell adhesion, clonogenic growth, and tumorigenicity via c-maf-mediated interactions with bone marrow stromal cells

CS1通过c-maf介导的与骨髓基质细胞的相互作用,促进多发性骨髓瘤细胞的黏附、克隆形成和致瘤性。

Tai, Yu-Tzu; Soydan, Ender; Song, Weihua; Fulciniti, Mariateresa; Kim, Kihyun; Hong, Fangxin; Li, Xian-Feng; Burger, Peter; Rumizen, Matthew J; Nahar, Sabikun; Podar, Klaus; Hideshima, Teru; Munshi, Nikhil C; Tonon, Giovanni; Carrasco, Ruben D; Afar, Daniel E H; Anderson, Kenneth C

Combinatorial efficacy of anti-CS1 monoclonal antibody elotuzumab (HuLuc63) and bortezomib against multiple myeloma

抗CS1单克隆抗体埃罗妥珠单抗(HuLuc63)与硼替佐米联合治疗多发性骨髓瘤的疗效

Frits van Rhee, Susann M Szmania, Myles Dillon, Anne M van Abbema, Xin Li, Mary K Stone, Tarun K Garg, JuMei Shi, Amberly M Moreno-Bost, Rui Yun, Balaji Balasa, Bishwa Ganguly, Debra Chao, Audie G Rice, Fenghuang Zhan, John D Shaughnessy Jr, Bart Barlogie, Shmuel Yaccoby, Daniel E H Afar

STEAP: a prostate-specific cell-surface antigen highly expressed in human prostate tumors

STEAP:一种在人类前列腺肿瘤中高表达的前列腺特异性细胞表面抗原

Hubert, R S; Vivanco, I; Chen, E; Rastegar, S; Leong, K; Mitchell, S C; Madraswala, R; Zhou, Y; Kuo, J; Raitano, A B; Jakobovits, A; Saffran, D C; Afar, D E